Global Antibacterial Drugs Market - 2023-2030

Global Antibacterial Drugs Market - 2023-2030

Global Antibacterial Drugs Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.

Antibacterial drugs are the type of antimicrobial substance that is active against bacteria. Antibacterial drugs can also interact with other drugs, raising or lowering serum levels of other drugs by increasing or decreasing their metabolism.

An antibiotic with bactericidal activity can improve bacterial killing when host defenses are impaired locally at the site of infection as in meningitis or endocarditis. Commonly used antibacterial drug classes include beta-lactams, aminoglycosides, macrolides, quinolones, quinolones, and sulfonamides.

Market Dynamics

Increasing drug approvals

Antibacterial drugs include a range of effective drugs that kill bacteria and inhibit their growth. The increasing approvals for antibacterial drugs act as a significant driver for market growth. Also, many key players play a major role in the advancements of the market by launching new therapeutic drugs.

For instance, in April 2023, the US Food and Drug Administration (FDA) granted final approval to Zydus Lifesciences 500mg azithromycin tablets for the treatment of bacterial infections. It is used in the treatment of infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.

Additionally, in March 2023, Glenmark Pharmaceuticals received the FDA approval for clindamycin hydrochloride capsules. This drug is used to treat certain types of bacterial infections, including infections of the lungs, skin, and blood.

Additionally, in September 2023, the U.S. FDA approved Appili Therapeutic’s liquid oral form of antibiotic drug metronidazole by offering an alternative to patients who have difficulty taking injections or pills

Furthermore, significant growth drivers such as rising incidence of chronic diseases, growing research in antibacterial drugs, and increasing clinical trials, are expected to drive the market in the forecast period.

Side effects associated with antibacterial drugs

Physicians prescribe antibiotics to prevent and treat bacterial infections. Although antibiotics can cause side effects ranging from minor to severe to life-threatening. Antibiotics can kill the good bacteria that protect people from fungal infections and disturb the natural balance of the body’s natural flora. It can also lead to low blood pressure, severe wheezing, and trouble breathing.

Segment Analysis

The global antibacterial drugs market is segmented based on action type, drug type, drug mechanism, route of administration, distribution channel, and region.

The beta-lactams segment accounted for approximately 39.7% of the market share

Beta-lactams are one of the most often prescribed antibiotic classes for antibacterial treatment which restrict bacterial growth by blocking penicillin-binding proteins, which are required for cross-linking during cell wall formation. Beta lactams are expected to hold the largest market share over the period forecast owing to increasing drug approvals for bacterial infections.

For instance, in January 2023, Alkem launched Zidavi, a novel combination of ceftazidime and avibactam. It is recommended by the IDSA and ICMR as a preferred treatment against OXA-48-like and Klebsiella Pneumoniae Carbapenemase (KPC)-producing Carbapenem-Resistant Enterobacteriaceae (CRE) for pyelonephritis.

Additionally, in May 2023, Innoviva Specialty Therapeutics declared that the U.S. FDA approved XACDURO (sulbactam for injection) which is co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia.

Geographical Analysis

North America is expected to hold a significant position in the global antibacterial drugs market share

The global antibacterial drugs market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of bacterial infections and drug approvals, this trend is anticipated to continue throughout the forecast period.

For instance, the National Institute of Health reported that in 2022, 8,300 tuberculosis cases were reported in the United States, compared with 7,874 in 2021. Tuberculosis incidence during 2022 increased slightly to 2.5 per 100,000 persons, compared with 2.4 during 2021. Hence, owing to the above factor, the demand for tuberculosis treatment drugs increases and helps in market growth.

Additionally, according to the Centers for Disease Control and Prevention 2022, pneumococcal pneumonia causes an estimated 150,000 hospitalizations each year in the United States. The number of visits to emergency departments with pneumonia as the primary diagnosis is 1.5 million and 50,000 deaths from pneumonia disease every year. Due to the increased prevalence of pneumonia cases, the production of bacterial pneumonia treatment drugs increases.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global antibacterial drugs market. The pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new treatment drugs. Therefore, the antibacterial drugs market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline Plc, Melinta Therapeutics, Eli Lilly and Company among others.

Key Developments
• In July 2023, Melinta Therapeutics, LLC, declared a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to promote the two antibiotics BAXDELA (delafloxacin) and VABOMERE (meropenem and vaborbactam), which are presently FDA-approved for adult use.
• In August 2023, Bugworks Research, entered a partnership with the Global Antibiotic Research and Development Partnership (GARDP) to boost the development of an antibiotic compound for treating serious infections caused by multidrug-resistant bacteria.
• On September 22, 2022, GSK plc and Spero Therapeutics, Inc. entered into an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic being developed by Spero, as the first oral carbapenem antibiotic to potentially treat complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.

Why Purchase the Report?
• To visualize the global antibacterial drugs market segmentation based on action type, drug type, drug mechanism, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global antibacterial drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global antibacterial drugs market report would provide approximately 77 tables, 82 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies